Swiss Auto Components Stock News

Roche Holding received CE Mark approval for its Elecsys pTau217 blood test for Alzheimer's disease in Europe. The assay is designed to detect amyloid pathology through a minimally invasive blood draw, supporting faster assessment in primary and secondary care. The approval adds to Roche's diagnostics portfolio in neurodegenerative disease and may influence how clinicians approach early Alzheimer's evaluation. For investors tracking SWX:ROP, the CE Mark arrives with the stock trading at...

Swisscom shares in focus after recent price move Swisscom (SWX:SCMN) has come into focus for investors after a recent share price move, with the stock last closing at CHF 678. This has drawn attention to its recent performance and valuation signals. See our latest analysis for Swisscom. Beyond the latest move to CHF 678, Swisscom’s recent momentum has been relatively steady, with a 30 day share price return of 2.57%, while the 1 year total shareholder return of 31.29% highlights the longer...

Recent performance snapshot UBS Group (SWX:UBSG) has drawn investor attention after a recent move in the share price, with the stock last closing at CHF 36.22. That puts its market value around CHF 106b. Over the past month, the stock has returned 9.6%, and over the past 3 months it has returned 12.4%. The 1 year total return stands at 35.0%, with a 3 year total return a little over 12x and a 5 year total return almost 20x. See our latest analysis for UBS Group. The recent 1 day share price...

The new CreativeX and CreatorIQ integration, developed with Nestlé (SWX:NESN), puts the company’s creator marketing under a single system. It automates content scoring and approval before paid media budgets are deployed worldwide. See our latest analysis for Nestlé. Despite the CreativeX and CreatorIQ integration highlighting Nestlé’s push to tighten its marketing workflows, the CHF77.32 share price sits against a mixed backdrop, with modest year to date share price gains but weaker multi...

PSP Swiss Property (SWX:PSPN) has opened Q1 2026 earnings season with trailing 12 month revenue of CHF 351.05 million and Basic EPS of CHF 8.91, backed by an 8.9% year over year improvement in earnings and supported by a one off gain of CHF 238.8 million that lifted reported profit. Over recent quarters, revenue has held in a tight band between CHF 87.44 million and CHF 88.65 million per quarter, while quarterly Basic EPS has ranged from CHF 1.32 to CHF 3.25. This has fed into that CHF 8.91...

The European market has experienced a week of volatility, with the pan-European STOXX Europe 600 Index achieving modest gains amidst easing geopolitical tensions and strong corporate earnings. However, potential tariff threats from the U.S. have introduced uncertainties that could impact future performance. In such an environment, stocks with high insider ownership can be appealing as they often indicate confidence in the company's growth prospects and alignment of interests between...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Q1 earnings set the tone for Swiss Re stock Swiss Re (SWX:SREN) put its first quarter on the table on May 7, reporting net income of US$1,506 million versus US$1,267 million a year earlier, alongside its Q1 2026 earnings call. See our latest analysis for Swiss Re. Despite the stronger Q1 net income, the stock has come under pressure, with the share price down 10.6% over the past month and the 1 year total shareholder return declining 14.08%, although the 5 year total shareholder return of...

INFICON Holding (SWX:IFCN) is back in focus after recent analyst updates and an annual general meeting where shareholders backed all proposals and approved a CHF 2.00 dividend, which has reinforced attention on the stock. See our latest analysis for INFICON Holding. INFICON Holding's recent AGM decisions and analyst updates come as the share price trades at CHF157.0, with a 1 month share price return of 36.8% and a 1 year total shareholder return of 63.0%, suggesting momentum has been...

Earlier this week, Sensirion Holding reported revenue growth of 18.58% alongside a zero-debt balance sheet and solid liquidity, reinforcing its financial strength. This combination of accelerating top-line performance and a clean capital structure adds an extra layer of resilience to Sensirion’s existing growth story. Next, we’ll examine how this strong revenue momentum and debt-free position may reshape Sensirion Holding’s existing investment narrative. Capitalize on the AI...

ABB (SWX:ABBN) has announced around US$200 million of investment in its European medium voltage operations, including a new facility in Italy and upgrades across several factories, to support demand for advanced grid technologies. See our latest analysis for ABB. ABB’s recent US$200 million grid investment program comes as the stock trades at CHF82.02, with a 30-day share price return of 14.17% and a 1-year total shareholder return of 78.50%, signalling strong momentum across both shorter and...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Readers hoping to buy Burkhalter Holding AG ( VTX:BRKN ) for its dividend will need to make their move shortly, as the...

Swiss Re AG ( VTX:SREN ) last week reported its latest first-quarter results, which makes it a good time for investors...

Recent share performance and business snapshot Clariant (SWX:CLN) has come into focus after a recent pullback, with the stock down about 7% over the past month and roughly 7% over the past 3 months, prompting investors to reassess its fundamentals. The Switzerland based specialty chemicals company operates across three main segments: Care Chemicals, Catalysts, and Adsorbents & Additives, serving customers across Europe, the Americas, Asia and the Middle East & Africa. See our latest analysis...

The European stock market recently experienced a volatile week, with modest gains in the pan-European STOXX Europe 600 Index, as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings. However, looming threats of increased tariffs from the U.S. added pressure to markets. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities that are potentially trading below their intrinsic value amidst fluctuating market...

In early May 2026, ams-OSRAM reported first-quarter sales of €796 million alongside a larger net loss and issued guidance for slightly softer full-year 2026 revenue due to business divestments and foreign-exchange effects. At the same time, the company highlighted progress in its Digital Photonics pivot, including a development partnership targeting AI data centers and micro LED commercialization, which has drawn renewed attention to its semiconductor portfolio. We’ll now examine how this...

Valiant Holding AG reported first-quarter 2026 results with net interest income of CHF 100.64 million and net income of CHF 33.24 million, both slightly higher than a year earlier. Despite this modest improvement, investors focused on the bank’s elevated debt levels and challenging revenue trends, which raised concerns about its financial flexibility and resilience. We’ll now examine how these weaker-than-expected earnings, alongside concerns over the high debt-to-equity ratio, shape Valiant...

Why Kuros Biosciences (SWX:KURN) is on investors’ radar today Kuros Biosciences (SWX:KURN) has drawn attention after recent share price pressure, with the stock showing a 15.1% decline over the past month and a 20.2% decline over the past 3 months. See our latest analysis for Kuros Biosciences. At the latest share price of CHF20.12, Kuros Biosciences shows weaker short term momentum, with a 1 month share price return of 15.1% decline and a year to date share price return of 24.6% decline,...

Novartis has started construction on a new radioligand therapy manufacturing facility in Denton, Texas. The Denton site expands the company’s US network for advanced cancer treatments and is part of a broader multi year, multi billion dollar US investment plan. The project is expected to support access to personalized cancer therapies and create jobs in bioengineering and advanced manufacturing. For investors following Novartis (SWX:NOVN), the Denton build out comes as the stock trades...

If you are asking whether UBS Group is priced attractively right now, the starting point is to look closely at what the current share price might already be assuming. The stock last closed at CHF 35.03, with returns of 1.5% over 7 days, 8.1% over 30 days, a 8.2% decline year to date, and gains of 38.4% over 1 year, 120.8% over 3 years and 189.1% over 5 years. Recent headlines have focused on UBS Group's role as a major global banking and wealth management group, including its ongoing...

Roche Holding (SWX:ROP) has entered a definitive agreement to acquire PathAI, a US-based provider of digital pathology and AI-powered diagnostic technologies. The deal is intended to expand Roche's digital pathology offering and support AI-driven diagnostics and precision oncology. The acquisition also aims to support biopharma partners with AI-enabled services in clinical trials and translational research. For Roche, which operates across pharmaceuticals and diagnostics, the PathAI deal...

If you are wondering whether Temenos is priced fairly or if the current share price leaves room for upside, it helps to start by looking closely at what the market has been paying for this stock recently. Temenos shares recently closed at CHF 74.20, with returns of 0.4% over 7 days, 2.3% over 30 days, a 9.0% decline year to date, and 22.6% over the past year. Together, these figures present a mixed picture of changing expectations and risk perception. Recent coverage of Temenos has focused...

If you are wondering whether Alcon at around $49.17 is starting to look like value after a tough spell, this breakdown will help you frame the opportunity and the risks. The stock has faced sharp share price pressure, with returns of a 15.5% decline over 7 days, a 19.7% decline over 30 days, a 22.6% decline year to date and a 37.9% decline over 1 year, as well as a 29.9% decline over 3 years and a 19.2% decline over 5 years. Recent coverage has focused on how this sustained weakness has put...